Clinical Trial Update: Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease [NA]

View source ↗

Summary

An ongoing clinical trial is evaluating Aponermin as a bridging therapy before CAR-T cell infusion for relapsed/refractory multiple myeloma with extramedullary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Aponermin (aponermin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Extramedullary Multiple Myeloma | NA | Status: RECRUITING